Pharmacokinetics and metabolism in drug discovery and preclinical development

Pharmacokinetics in Drug Discovery and Development

Volumn , Issue , 2002, Pages 57-71

  Modi, Nishit B ^a  

^a ALZA CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 9744260435     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (44)

1. Peck, C. C. et al., Opportunities for integration of pharmacokinetics, pharmacodynamics, and toxicokinetics in rational drug development, J. Clin. Pharmacol., 34: 111-119, 1994.
2. Wills, R. J. and Ferraiolo, B. L., The role of pharmacokinetics in the development of biotechnologically derived agents, Clin. Pharmacokinet., 23: 406-414, 1992.
3. Smith, P. L., Methods for evaluating intestinal permeability and metabolism in vitro, in Models for Assessing Drug Absorption and Metabolism, Borchardt, R. T., Smith, P. L., and Wilson, G., Eds., Plenum Press, New York, 1996, 13-34.
4. Hunter, J., Hirst, B. H., and Simmons, N. L., Epithelial secretion of vinblastine by human intestinal adenocarcinoma cell (HCT-8 and T84) layers expressing P-glycoprotein, Br. J. Cancer, 64: 437-444, 1991.
5. Gan, L. S. et al., Use of Caco-2 cells as an in vivo intestinal absorption and metabolism model, Drug Dev. Ind. Pharm., 20: 615-631, 1994.
6. Gan, L. S. I. and Thakker, D. R., Applications of the Caco-2 model in the design and the development of orally active drugs: elucidation of biochemical and physical barriers posed by the intestinal epithelium, Adv. Drug Deliv. Res., 23: 77-98, 1997.
7. Barthe, L., Woodley, J., and Houin, G., Gastrointestinal absorption of drugs: methods and studies, Fundam. Clin. Pharmacol.,13: 154-168, 1999.
8. Ussing, H. H., Transport of ions across cellular membranes, Physiol. Rev., 29: 127-155,1949.
9. Hegel, U. et al., Bovine and porcine large intestine as model epithelia in a student lab course, Adv. Phys. Ed., 10: S10-S19, 1993.
10. Field, M., Fromm, D., and McColl, I., Ion transport in rabbit ileal mucosa. I. Na and Cl fluxes and short-circuit current, Am. J. Physiol., 220: 1388-1396, 1971.
11. Wilson, T. H. and Wiseman, G., The use of sacs of everted small intestine for the study of the transference of substance from the mucosal to the serosal surface, J. Physiol., 123: 116-125, 1954.
12. Yuasa, H., Matsuda, K., and Watanabe, J., Influence of anesthetic regimens on intestinal absorption in rats, Pharm. Res., 10: 884-888, 1993.
13. Doluisio, J. T. et al., Drug absorption I: an in situ gut technique yielding realistic absorption rates, J. Pharm. Sci., 58: 1196-1200, 1969.
14. Lewis, L. D. and Fordtran, J. S., Effect of perfusion rate on absorption, surface area, unstirred water layer thickness, permeability and intraluminal pressure in the rat ileum in vivo, Gastroenterology, 68: 1509-1516, 1975.
15. Kararli, T. T., Comparison of the gastrointestinal anatomy, physiology, and biochemistry of humans and commonly used laboratory animals, Biopharm. Drug Dispos., 16: 351-380, 1995.
16. Allen, M. C., Shah, T. S., and Day, W. W., Rapid determination of oral pharmacokinetics and plasma free fraction using cocktail approaches: methods and applications, Pharm. Res., 15(1): 93-97, 1998.
17. Shaffer, J. E. et al., Use of “N-in One” dosing to create an in vivo pharmacokinetic database for use in developing structure-pharmacokinetic relationships, J. Pharm. Sci., 88: 313-318, 1999.
18. Hop, C. E. C. A. et al., Plasma-pooling methods to increase throughput for in vivo pharmacokinetic screening, J. Pharm. Sci., 87: 901-903, 1998.
19. Rodrigues, A. D., Preclinical drug metabolism in the age of high-throughput screening: an industrial perspective, Pharm. Res., 14: 1504-1510, 1997.
20. Tucker, G. T., The in vivo assessment of human hepatic drug metabolism, in Handbook of Phase I/II Clinical Drug Trials, O’Grady, J. and Joubert, P. H., Eds., CRC Press, Boca Raton, FL, 1997, 51-63.
21. Welling, P. G., Role of pharmacokinetics in drug discovery and development, in Pharmacokinetics of Drugs, Welling, P. G. and Balant, L. P., Eds., Springer-Verlag, Heidelberg, 1994, 3-19.
22. McGuill, M. W. and Rowan, A. N., Biological effects of blood loss: implications for sampling volumes and techniques, ILAR News, 31: 5-20, 1989.
23. Bouzom, F. et al., Use of nonlinear mixed effect modeling for the meta-analysis of preclinical pharmacokinetic data: application to S 20342 in the rat, J. Pharm. Sci., 89: 603-613, 2000.
24. Gething, P. A. and Daley-Yates, P. T., A sparse sampling, mixed effects approach to toxicokinetic analyses, Drug Inf. J., 31: 521-527, 1997.
25. Burtin, P. et al., Sparse sampling for assessment of drug exposure in toxicological studies, Eur. J. Drug Metab. Pharmacokinet., 21: 105-111, 1996.
26. Pai, S. M. et al., Characterization of AUCs from sparsely sampled populations in toxicology studies, Pharm. Res., 13: 1283-1290, 1996.
27. Mordenti, J. and Chappell, W., The use of interspecies scaling in toxicokinetics, in Toxicokinetics and New Drug Development, Yacobi, A., Skelly, J. P., and Batra, V. K., Eds., Pergamon Press, Elmsford, NY, 1989, 42-96.
28. Chappell, W. R. and Mordenti, J., Extrapolation of toxicological and pharmacological data from animals to humans, Adv. Drug Res., 20: 1-116, 1991.
29. Lave, T. et al., Interspecies scaling of interferon disposition and comparison of allometric scaling with concentration-time transformations, J. Pharm. Sci., 84: 1285-1290, 1995.
30. Lave, T. et al., Animal pharmacokinetics and interspecies scaling from animals to man of lamifiban, a new platelet aggregation inhibitor, J. Pharm. Pharmacol., 48: 573-577, 1996.
31. Lave, T. et al., Interspecies pharmacokinetic comparisons and allometric scaling of napsagartran, a low molecular weight thrombin inhibitor, J. Pharm. Pharmacol., 51: 85-91, 1999.
32. Feng, M. R. et al., Allometric pharmacokinetic scaling: towards the prediction of human oral pharmacokinetics, Pharm. Res., 17: 410-418, 2000.
33. Mordenti, J. et al., Interspecies scaling of clearance and volume of distribution data for five therapeutic proteins, Pharm. Res., 8: 1351-1358, 1991.
34. Khor, S. P. et al., Pharmacokinetics, pharmacodynamics, allometry, and dose selection of rPSGL-Ig for Phase I trial, J. Pharmacol. Exp. Ther., 293: 618-624, 2000.
35. Lin, Y. S. et al., Preclinical pharmacokinetics, interspecies scaling and tissue distribution of a humanized monoclonal antibody against vascular endothelial growth factor, J. Pharmacol. Exp. Ther., 288: 371-378, 1999.
36. Modi, N. B. et al., Pharmacokinetics and pharmacodynamics of TP-9201, a gpIIbIIIa antagonist, in rats and dogs, J. Cardiovasc. Pharmacol., 25: 888-897, 1995.
37. Eppler, S. et al., Pharmacokinetics and pharmacodynamics of recombinant tissuetype plasminogen activator following intravenous administration in rabbits: comparison of three dosing regimens, Biopharm. Drug Dispos., 19: 31-38, 1998.
38. Modi, N. B. et al., Pharmacokinetics and pharmacodynamics of TP-9201, a gpIIbIIIa antagonist, administered in combination with Activase® t-PA, heparin, and aspirin in beagles, J. Cardiovasc. Pharmacol., 27: 105-112, 1996.
39. Modi, N. B. et al., Pharmacokinetics and pharmacodynamics of sibrafiban (Ro 48-3657), an orally active IIbIIIa antagonist, administered alone or in combination with heparin, aspirin and recombinant tissue-type plasminogen activator in beagles, J. Cardiovasc. Pharmacol., 32: 397-405, 1998.
40. Refino, C. J. et al., Pharmacokinetics, pharmacodynamics, and tolerability of a potent, non-peptidic, GP IIb/IIIa receptor antagonist following multiple oral administration of a prodrug form, Thromb. Haemost, 79: 169-176, 1998.
41. Veng-Pedersen, P. et al., A system approach to pharmacodynamics. Plasma iron mobilization by endogenous erythropoietin in the sheep fetus; evidence of threshold response in spontaneous hypoxemia, J. Pharm. Sci., 82: 804-807, 1993.
42. Mordenti, J. et al., Efficacy and concentration-response of murine anti-VEGF monoclonal antibody in tumor-bearing mice and extrapolation to humans, Toxicol. Pathol., 27: 14-21, 1999.
43. Parkinson, A., Biotransformation of xenobiotics, in Casarett & Doull’s Toxicology, The Basic Science of Poisons, 5th ed., Klaassen, C. D., Ed., McGraw-Hill, New York, 1996, 113-186.
44. Michalets, E. L., Update: clinically significant cytochrome P-450 drug interactions, Pharmacotherapy, 18: 84-112, 1998.